Cancer Immunotherapy Meets Oncology: In Honor of Christoph Huber
Editat de Cedrik Michael Britten, Sebastian Kreiter, Mustafa Diken, Hans-Georg Rammenseeen Limba Engleză Hardback – 7 mai 2014
Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 775.04 lei 38-44 zile | |
Springer International Publishing – 23 aug 2016 | 775.04 lei 38-44 zile | |
Hardback (1) | 714.32 lei 3-5 săpt. | |
Springer International Publishing – 7 mai 2014 | 714.32 lei 3-5 săpt. |
Preț: 714.32 lei
Preț vechi: 751.92 lei
-5% Nou
Puncte Express: 1071
Preț estimativ în valută:
136.71€ • 142.00$ • 113.55£
136.71€ • 142.00$ • 113.55£
Carte disponibilă
Livrare economică 11-25 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319051031
ISBN-10: 3319051032
Pagini: 246
Ilustrații: IX, 248 p. 19 illus., 18 illus. in color.
Dimensiuni: 178 x 254 x 17 mm
Greutate: 0.75 kg
Ediția:2014
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3319051032
Pagini: 246
Ilustrații: IX, 248 p. 19 illus., 18 illus. in color.
Dimensiuni: 178 x 254 x 17 mm
Greutate: 0.75 kg
Ediția:2014
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
Public țintă
ResearchCuprins
Immunological and Regulatory Framework for Immuno-Oncology: From Basic Immunology to New Therapies for Patients.- How T cells single out tumor cells: 'and that has made all the difference'.- Tregs and Immune Inhibition.- Regulatory Landscape for Cancer Immunotherapy.- Immunoguiding.- Onco-Immunology Framework and Immunomodulatory Antibodies.- Immunotherapies: Peptide-based Vaccines and HPV Malignancies.- Dendritic cell based cancer vaccines.- RNA Vaccines and Personalized Medicine Approaches.-Antibody Therapy in Oncology.- Engineered Antibodies to Engage Immune Cells to the Tumor.- TCRs and TCR Therapy.- CAR Therapy.- Cancer Entities: Melanoma.- Prostate Cancer/Sipuleucel and RNA Vaccines.- Recent advances in the immunotherapy of renal cell cancer and other solid tumors.- Gastric Cancer.- NSCLC.- Breaking tolerance by allogeneic lymphocyte therapy.- Biomarkers: Exploring Immunogenic Cell Death for Patient Benefit.- Circulating Tumor Cells.- Genomics Meets Oncology.- Featured Chapters: Oncolytic Viruses.- Pharma View on Immunotherapy.- Final Remarks.
Textul de pe ultima copertă
This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing.
Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
Caracteristici
Provides a comprehensive update on the state of the art in cancer immunology Describes the most promising therapeutic concepts, with coverage of combination therapies and personalized medicine Discusses the role of biomarkers in guiding the clinical development of new treatment approaches